avagacestat   Click here for help

GtoPdb Ligand ID: 6489

Synonyms: BMS-708163
PDB Ligand
Compound class: Synthetic organic
Comment: Avagacestat is an oral gamma-secretase inhibitor designed for the selective inhibition of A-beta generation relative to Notch substrates in the treatment of Alzheimer's Disease but Phase 2 data did not support advancement to Phase 3
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 6
Hydrogen bond donors 1
Rotatable bonds 10
Topological polar surface area 127.77
Molecular weight 520.06
XLogP 4.63
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES NC(=O)C(N(S(=O)(=O)c1ccc(cc1)Cl)Cc1ccc(cc1F)c1nocn1)CCC(F)(F)F
Isomeric SMILES NC(=O)[C@H](N(S(=O)(=O)c1ccc(cc1)Cl)Cc1ccc(cc1F)c1nocn1)CCC(F)(F)F
InChI InChI=1S/C20H17ClF4N4O4S/c21-14-3-5-15(6-4-14)34(31,32)29(17(18(26)30)7-8-20(23,24)25)10-13-2-1-12(9-16(13)22)19-27-11-33-28-19/h1-6,9,11,17H,7-8,10H2,(H2,26,30)/t17-/m1/s1
InChI Key XEAOPVUAMONVLA-QGZVFWFLSA-N
References
1. Alzheimer Research Forum. 
DRUGS IN CLINICAL TRIALS: BMS-708163.
Accessed on 06/09/2013. Modified on 06/09/2013. Alzheimer Research Forum, http://www.alzforum.org/drg/drc/detail.asp?id=124
2. Coric V, van Dyck CH, Salloway S, Andreasen N, Brody M, Richter RW, Soininen H, Thein S, Shiovitz T, Pilcher G et al.. (2012)
Safety and tolerability of the γ-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease.
Arch Neurol, 69 (11): 1430-40. [PMID:22892585]